Claims for Patent: 10,736,918

Summary for Patent: 10,736,918

Title:	Method and compositions for cellular immunotherapy
Abstract:	The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
Inventor(s):	Michael C. Jensen, Stanley R. Riddell, Michael Hudecek
Assignee:	Fred Hutchinson Cancer Center
Application Number:	US15/817,002

Details for Patent 10,736,918

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Juno Therapeutics, Inc. A Bristol Myer-squibb Company	BREYANZI	lisocabtagene maraleucel	Injection	125714	February 05, 2021		2037-11-17

International Patent Family for US Patent 10,736,918

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2014031687
United States of America	2024390491
United States of America	2021052649
United States of America	2020078405
United States of America	2018200298
United States of America	2015306141